← All indications
Adenocarcinoma of Lung
A carcinoma originating in the lung and the most common lung cancer type in never-smokers. Malignant cells exhibit distinct features such as glandular epithelial, or tubular morphology. Mutations in KRAS, EGFR, BRAF, and ERBB2 genes are associated with this cancer.
Subtype terms (1)
More specific conditions that are subtypes of Adenocarcinoma of Lung in the MeSH hierarchy.
- Adenocarcinoma, Bronchiolo-Alveolar
7 drugs (6 approved, 1 experimental)
Drugs by status
Phase 4 trials (5)
Phase 3 trials (10)
Phase 2 trials (52)
- icotinib
- orlistat
- anlotinib
- auranofin
- berberine
- cixutumumab
- alpha (1,3) galactosyltransferase expressing allogeneic tumor cells
- durvalumab
- etarfolatide
- farletuzumab
- imatinib
- gm.cd40l vaccine
- trametinib
- lapatinib
- nintedanib
- aldesleukin
- Luminespib
- Filgrastim
- als-008176
- l-dos47
- lmb-100
- methoxyamine
- msk-2206
- ss1(dsfv)pe38
- osimertinib
- pentostatin
- ponatinib
- sitagliptin
- sirolimus
- cyclophosphamide
- +22 more
Phase 1 trials (20)
- autologous tumor infiltrating lymphocytes
- binimetinib
- fulvestrant
- photochlor
- palbociclib
- methylene blue
- mesothelin car t cells
- dapagliflozin
- letrozole
- soybean
- sargramostim
- sintilimab
- ibi188
- il13ralpha2-specific hinge-optimized 4-1bb-co-stimulatory car/truncated cd19-expressing autologous tn/mem cells (Biological)
- imu-201
- py159
- py314
- pf-07220060
- amt-151
- nm32-2668
Organizations
Organization Involved with Phase 4 Indications (8)
Organization Involved with Phase 3 Indications (23)
- Bristol-Myers Squibb
- Celltrion
- Synta Pharmaceuticals Corp.
- BioNumerik Pharmaceuticals, Inc.
- National Cancer Institute (NCI)
- National Center for Complementary and Integrative Health (NCCIH)
- Huazhong University of Science and Technology
- Canadian Cancer Trials Group
- Cancer and Leukemia Group B (CALGB)
- Centre Hospitalier Intercommunal Creteil
- Eastern Cooperative Oncology Group
- Institut Bergonié
- Radiation Therapy Oncology Group
- Seoul National University
- Shanghai University of Traditional Chinese Medicine
- Southwest Oncology Group
- Sichuan University
- Fudan University
- Groupe Francais De Pneumo-Cancerologie
- Jiao Tong University
- Shanghai University
- University of Texas at Houston
- Chinese Academy of Medical Sciences
Organization Involved with Phase 2 Indications (91)
- Incyte
- Regeneron
- Eisai
- Celgene
- Amgen
- OSI Pharmaceuticals
- Morphotek
- AstraZeneca
- Merck
- Genentech
- Pfizer
- Sanofi
- AIO-Studien-gGmbH
- Novartis
- Ariad Pharmaceuticals
- Axelar AB
- Bayer
- Endocyte
- GlaxoSmithKline
- Helix BioPharma Corporation
- Hengrui Therapeutics, Inc.
- MedicalLogic
- National OncoVenture
- Simcere Pharmaceutical Co., Ltd
- BerGenBio ASA
- Boehringer Ingelheim
- National Cancer Center, Korea
- Rongjie Tao
- University of Pennsylvania
- Changhai Hospital
- +61 more
Organization Involved with Phase 1 Indications (11)
Organization Involved with Other Experimental Indications (7)